Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Vitrakvi (larotrectinib) binds to and prevents activation of TRK receptors (NTRK1, -2, -3), resulting in decreased growth and increased apoptosis in Trk-expressing tumor cells (PMID: 29532798). Vitrakvi (larotrectinib) is FDA approved for use in adult and pediatric patients with solid tumors that have progressed, are metastatic, or are not surgically resectable and have an NTRK fusion without acquired resistance mutations (FDA.gov).
|DrugClasses||Trk Receptor Inhibitor (Pan) 23|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Dabrafenib + Larotrectinib + Trametinib||Dabrafenib Larotrectinib Trametinib||0||0|
|Fulvestrant + Larotrectinib||Fulvestrant Larotrectinib||0||0|
|Larotrectinib + Trametinib||Larotrectinib Trametinib||0||0|